Kynamro (mipomersen sodium)
- Region
- 🇪🇺 EU
- Active substance
- mipomersen sodium
- Company
- Genzyme Europe BV
- Status
- Refused
- Therapeutic area
- Hypercholesterolemia
- CHMP opinion
- Thu 21 Mar 2013
- Application
- EMEA/H/C/002429
- ATC
- C10AX11
- Official record
- www.ema.europa.eu
Indication
treatment of cholesterol and hypercholesterolaemia
Regulatory milestones
No milestones recorded in the last year.
Follow Kynamro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.